BXQ 350

Drug Profile

BXQ 350

Alternative Names: BXQ-350; SapC-DOPS; Saposin C coupled-phospholipid dioleoylphosphatidylserine

Latest Information Update: 22 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bexion Pharmaceuticals
  • Developer Bexion Pharmaceuticals; Cincinnati Children's Hospital Medical Center
  • Class Antineoplastics; Phosphatidylserines; Saposins
  • Mechanism of Action Apoptosis stimulants; Sphingomyelin phosphodiesterase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioma; Solid tumours

Most Recent Events

  • 12 Sep 2016 Phase-I clinical trials in Glioma in USA (IV) (NCT02859857)
  • 12 Sep 2016 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV) (NCT02859857)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top